The FDA has authorized 26 nicotine pouch products in the past 13 months. In the same period, it has authorized zero flavored disposable vape products. Retail category velocity data confirms what the regulatory pipeline already made inevitable — nicotine pouches are no longer a niche adjacency to the vape business. They are displacing it.
This briefing covers what’s happening across U.S. retail right now, why it’s happening, where the category inversion is heading through year-end 2026, and which industry players are positioned for the shift.
📋 Executive Summary
The headline finding: The U.S. nicotine category is undergoing a structural inversion. Nicotine pouches — previously a rounding-error in a vape-dominated category — are on track to represent 20–25% of the U.S. smoke-free nicotine retail spend by end of 2026, up from under 8% in 2022.
Four forces driving the shift: (1) A regulatory fast-track pilot from FDA that has moved pouches from zero to 26 authorized SKUs while vape PMTAs remain stalled; (2) Congressional allocation of $200 million to FDA vape enforcement for FY2026; (3) Consumer switching patterns driven by office-space restrictions, weekly cost pressure, and perceived respiratory risk; (4) Big Tobacco capital reallocation — $735M+ in announced U.S. pouch manufacturing investment across PMI, Swisher, and Reynolds since 2024.
What retailers should expect by Q4 2026: Continued disposable enforcement escalation at ports of entry (“seize and destroy” authority now active). Additional pouch PMTA authorizations. Accelerated shelf reallocation at convenience and gas-station retail. State-level flavor legislation targeting both categories but affecting unauthorized vapes more immediately than authorized pouches.
(13 months)
(4 years)
through 2030
FY2026
capex announced
seizures capture (GAO)
1. The Regulatory Pivot: Why Pouches Got the Green Light Vapes Didn’t
The story of the 2025–2026 category inversion begins with a regulatory decision that got minimal attention when it happened: in September 2025, the FDA’s Center for Tobacco Products launched a pilot program specifically designed to accelerate PMTA reviews for nicotine pouches. The stated goal was to “increase efficiency and streamline” the review process through real-time communication with applicants and shorter review timeframes.
The results came quickly. Here’s the authorization timeline industry observers should commit to memory:
B&J Wholesale’s pouch distribution inventory — the commercial reality of the category expansion. Retailers rebalancing toward pouches are sourcing ZYN, OEO, Breakers, and G-Pulse at wholesale velocity that wasn’t present 24 months ago. B&J Wholesale distribution profile →
2. The Capital Flow: Big Tobacco Votes With Its Checkbook
Regulatory signals often lag industry capital commitments, not the other way around. The pouch category’s current trajectory was arguably visible in the announced capital expenditure from incumbent tobacco operators well before the FDA authorizations arrived.
Announced U.S. pouch manufacturing investment (2024–2025)
| Announcement | Company | Investment | Location / Purpose |
|---|---|---|---|
| July 2024 | Philip Morris International | $600 million | New ZYN manufacturing facility in Colorado |
| August 2024 | Philip Morris International | ~$250 million | Expansion of existing ZYN production |
| March 2025 | Reynolds American (BAT) | Not disclosed | Operations center expansion, Tobaccoville, NC — domestic pouch supply hub |
| December 2025 | Swisher International | $135 million | “Project Newark” — automated pouch operations, Springfield |
| June 2023 | Imperial Brands (ITG) | Not disclosed | TJP Labs portfolio acquisition for U.S. market entry |
| Total disclosed | $735M+ | Across 18 months |
PMI’s nearly $850M combined ZYN commitment alone — between the $600M Colorado greenfield facility and the $250M production expansion — is a capital signal that the operator with the most category-specific data is betting on a long category trajectory, not a short spike.
3. The Consumer Shift: What the Retail Data Actually Shows
The macroeconomic and regulatory backdrop is one thing. The retail floor data is the proof. Here’s what’s measurable as of Q1 2026:
Category growth rates (U.S.)
| Category | 2024 Market Size | Projected CAGR | Share of Sales Online | Youth Use (CDC/FDA 2024) |
|---|---|---|---|---|
| Nicotine pouches (U.S.) | $4.09 billion | 29.6% through 2030 | ~40% (N.A.) | 1.5% of youth; ZYN 1.8% of M/HS students |
| Disposable vapes (U.S.) | ~$7.3 billion* | Flat to single-digit | ~25% (est.) | ~5.9% of HS students (historically higher) |
*Total U.S. vape market including disposables, pod systems, and refillables. Disposables specifically represent approximately 60% of that total per retail trade data.
The four consumer drivers
Conversations with distributors, retailers, and consumer research firms point to four convergent forces driving vapers toward pouches in 2026:
Driver 1: Use-Case Displacement
The defining behavioral shift. A vape disposable cannot be used inside most U.S. offices, on flights, in restaurants, or in an increasing range of indoor public spaces. Pouches can be. As “work from office” return-to-work mandates landed through 2024–2025, the share of a daily nicotine user’s “nicotine day” that had to occur outside vape-appropriate settings expanded meaningfully. The “Silicon Valley Phenomenon” reported by HDIN Research — with Big Tech and startup offices stocking pouches in fridges and vending machines — is one visible data point in this pattern.
Driver 2: Weekly Cost Economics
Goldman Sachs research on U.S. nicotine consumer behavior (Herzog, Q4 2023, updated 2025) notes that “tobacco consumers remain under substantial financial pressure” and are increasingly turning to “more affordable alternatives, such as 4th tier/deep discount cigarettes, modern oral tobacco, and, increasingly, illicit or gray market disposable vapor products.” Weekly pouch spend at normal use patterns runs $8–$15. Heavy disposable use runs $15–$25. For consumers feeling budget pressure, this delta matters.
Driver 3: Respiratory Risk Perception
Consumer awareness campaigns and sustained news coverage of vaping-related respiratory issues from 2019–2023 continue to shape purchase behavior years later. Even as the acute “EVALI” episode (linked primarily to illicit THC vapes) faded from headlines, the residual perception — that pouches avoid lung exposure entirely — has become a primary stated reason for switching. The American Cancer Society’s recent cautionary framing of pouches as “lower risk but not risk-free” has not slowed the switch.
Driver 4: Regulatory Legitimacy Asymmetry
The FDA authorization of flavored pouch products (ZYN in 20 SKUs, on! PLUS in 6) with no equivalent authorization for flavored vapes has created a consumer-legible difference. Vapers who read tobacco-policy news — and many do, particularly heavier users — have increasingly come to understand that the flavored disposable they buy is in regulatory limbo while the flavored pouch available next to it on the counter is federally cleared. This is a quiet but structurally important perceptual shift.
4. The Enforcement Pressure: Why Unauthorized Disposables Are Exposed
The pouch category’s tailwind is only half of the story. The disposable category’s headwind is the other half.
Enforcement escalation in FY2026
- $200 million FDA enforcement allocation specifically for vapor products
- “Seize and destroy” authority at U.S. ports of entry — new under FY2026 Agriculture Appropriations legislation. Previously, customs could only refuse entry; now imports can be destroyed immediately.
- Multi-agency task force (FDA + DOJ + DHS) expanded coordination on port-of-entry actions
- $21,000+ per-violation FDA civil penalties for unauthorized retail sales
- 13 states operating vapor product directory laws with $2K–$50K per-SKU fines for unlisted products
- California AB 762 — proposed ban on all battery-embedded single-use vapes by mid-2026 (environmental framing)
But the GAO April 2026 report is the critical counterpoint. Its finding that enforcement actions have been “falling short” — with the 3 million-unit, $76M-retail-value 2024 seizure representing only ~4% of a single month’s Chinese vape exports to the U.S. — confirms what distributors see on the ground. Enforcement is escalating but not displacing the illicit disposable supply. The category remains supplied; what’s changing is risk exposure for the retailers stocking it.
For retailers, this asymmetry is the operative factor. Stocking unauthorized flavored disposables doesn’t result in immediate product scarcity, but it does mean exposure to state registry fines, FDA civil penalties, and — in the states where local enforcement is active — escalating practical consequences. Stocking authorized pouches doesn’t have those exposures.
For full regulatory background see our “Built in USA” Playbook analyzing the brand-origin arbitrage some operators are attempting, and our ongoing Policy & Regulation Tracker.
5. The Retail Category Inversion: What’s Happening at Shelf
The macro picture translates into specific behaviors that distributors and retailers are observing across U.S. channels:
Shift signals at retail (observed Q4 2025 – Q1 2026)
| Retail Signal | Direction | Magnitude |
|---|---|---|
| Convenience channel pouch facings | ↑ Expanding | Typical c-store pouch SKU count up 40–80% YoY at major chains |
| Disposable vape facings | ↓ Contracting (unauthorized) | Some chains quietly reducing unauthorized SKU count ahead of enforcement risk |
| ZYN out-of-stock incidents | ↑ Rising | Reported as persistent issue through 2024–2025; PMI Colorado facility response |
| Repurchase cycle velocity | ↑ Higher in pouches | Pouches: 2–4 days. Disposables: 1–3 weeks. |
| Dual-category customers | ↑ Growing | Consumer research shows significant share of adopters maintaining vape+pouch dual use |
| State pouch excise tax proposals | ↑ Accelerating | Multiple states including NY considering pouch-specific excise in 2026 budget cycles |
The practical effect at shelf: retailers who are ahead of this have been reallocating 10–30% of counter and behind-register space from disposables to pouches over 12 months. Retailers who are behind are starting to experience the conversation in a different way — ZYN stockouts, customers asking for OEO or G-Pulse by name, and flatter disposable sell-through even against a growing denominator of foot traffic.
6. What Comes Next: Outlook Through Q4 2026
Based on current trajectory, here’s what VapeTrends360 expects to see develop through the remainder of 2026:
7. Winners, Exposed Players, and What to Watch
Industry positioning matrix
🟢 Well-positioned for the shift
Philip Morris International / Swedish Match (ZYN): Category anchor, 58.8% share, FDA-authorized, manufacturing capacity coming online. Lead position in the fastest-growing nicotine category.
Altria (On! / On! PLUS): Second mover with December 2025 authorization. Real beneficiary of the “dual use transition” language FDA used in the on! PLUS authorization.
Diversified distributors: Wholesalers carrying both vape and pouch inventory (e.g., B&J Wholesale, Mi-Pod, regional equivalents) are positioned for the rotation without losing existing revenue base.
Retailers who stock both formats: Higher per-customer LTV, less regulatory exposure per retail dollar, better positioned against store-level margin pressure.
🔴 Exposed to the shift
Unauthorized flavored disposable brands: Port seizure risk, state directory fines, no FDA authorization pathway. Most of the “new Made in USA” disposable entrants covered in our Built in USA Playbook sit here.
Single-format vape retailers: Businesses built entirely on disposable velocity face a category with flat-to-declining growth while their fixed cost base increases (rent, labor, compliance).
Small pouch entrants: FDA pilot program participants benefit first. Brands not in the pilot face a longer, more expensive authorization path and limited ability to carry flavored SKUs at scale in the interim.
🟡 Watch-list for 2026
Synthetic nicotine pouches: BAT’s Velo Plus launch and FDA’s stated openness to synthetic nicotine under PMTA pathways could accelerate this subsegment. Synthetic held 86.1% of global pouch market share in 2024.
Bioceramic / controlled-release pouches: Emplicure’s KLAR (UK launch April 2025) signals the format innovation next wave. If it lands well in Europe, U.S. entry in 2026–2027 is probable.
State excise tax legislation: Pouch-specific taxes in major states would compress the unit economics advantage pouches currently enjoy. Watch NY, CA, MA, and IL in 2026 budget cycles.
❓ Frequently Asked Questions
Is “pouches replacing vapes” an overstatement or is this really structural?
It’s structural. The regulatory, capital, and consumer-behavior data all point in the same direction. That said, “replacement” is the wrong frame — pouches are taking share from disposables specifically, not displacing the entire vape category. Pod systems, refillables, and the FDA-authorized ENDS products (NJOY, Vuse, Logic) aren’t in the same competitive frame. The part of the vape category most exposed is unauthorized flavored disposables, which is also the part under the most enforcement pressure.
How many nicotine pouch PMTA authorizations should the industry expect in 2026?
FDA has not published specific targets, but the pilot program structure suggests decisions on the named candidates — Zyn Ultra, Velo mini, FRE, Alp, and additional On! / On! PLUS expansions — could arrive through H2 2026. A reasonable expectation is 10–30 additional SKU authorizations by year-end. If that materializes, total FDA-authorized pouch SKUs would reach 35–55+ versus the 41 total authorized ENDS products (all tobacco/menthol) that currently represent the total authorized vape field.
Can flavored disposables ever get FDA authorization?
Under current FDA application of the PMTA framework, it’s extremely unlikely in the near term. The agency has consistently held that flavored ENDS products pose unique youth-appeal risk, and no flavored vape has successfully demonstrated the “appropriate for the protection of public health” standard with FDA to date. Manufacturers holding pending applications include major international firms, but the track record is unambiguous: over four years into PMTA reviews, zero flavored vape products have been authorized. Pouches received pilot treatment; vapes have not.
What’s the outlook for dual-use consumers (vape + pouch)?
This is the most underappreciated consumer segment in the category right now. Consumer research consistently shows a meaningful share of former-smoker adult nicotine users maintaining both formats simultaneously — vape for leisure/home contexts, pouch for work/travel/public contexts. FDA’s on! PLUS authorization notably acknowledged dual use as a “transitional phase” for smoker switchers. This segment is likely to represent 30–40% of adult nicotine consumers by end of 2026 based on current trajectory, which makes the “pick one” framing less operationally relevant than retailers might assume.
Should retailers expect pouch youth-use enforcement to intensify?
Yes, but more gradually than vape enforcement did. CDC/FDA 2024 data shows 1.5% of U.S. youth using pouches, with ZYN at 1.8% of middle/high school students. The Truth Initiative’s January 2026 report flagged pouches as a youth-use concern alongside smart vapes. Regulatory attention will likely increase but the absolute usage base is smaller than vapes were at their 2019–2020 peak, and the flavored pouch authorizations FDA has granted came after considering youth data. Expect age verification and retail point-of-sale enforcement to tighten, but a full flavor restriction on pouches is unlikely under current FDA posture.
What’s B&J Wholesale’s role in this shift?
B&J Wholesale is a licensed U.S. B2B distributor operating in the category segment most directly shaped by the 2026 inversion. The company stocks both vape and pouch inventory (including ZYN, OEO, Breakers, G-Pulse, alongside its disposable vape program) for approved private clients — the dual-category retailer archetype positioned best for 2026. Its current product mix reflects the retail reallocation underway: pouches as a growing share of the wholesale order book without displacing the existing vape program. For retailers evaluating inventory rebalancing, the wholesale-channel view provides useful forward signal on what will reach consumer shelves in subsequent quarters.
Where does VapeTrends360 sit on the pouch-vs-vape “which is better” question?
We don’t take a product-level advocacy position. Our role is industry analysis. From a regulatory compliance standpoint, authorized pouches currently carry lower retail-channel exposure than unauthorized flavored disposables — that’s a factual observation, not an endorsement. From a public-health standpoint, both categories involve addictive nicotine and both are harm-reduction products rather than risk-free alternatives, with different physiological profiles (respiratory for vapes, oral for pouches). Our consumer-side companion analysis on VapeOwls covers the adult-consumer decision framework in detail.
📌 Editorial Takeaway
The 2025–2026 nicotine category story is being written in two directions at once. Pouches are expanding through FDA authorization, Big Tobacco capex, and consumer switching. Disposables are contracting through enforcement escalation, regulatory-pathway deadlock, and the state-level directory expansion. These are not mirror-image forces — they are independent vectors arriving at the same retail shelf.
For industry participants, the practical question isn’t whether the inversion is real (it is) or how fast it’s happening (faster than widely appreciated in vape-industry trade press). It’s how fast each player’s business model can adapt. Distributors and retailers with dual-format capability are positioned well. Single-format operators on either side face increasing pressure.
VapeTrends360 will continue tracking pouch PMTA decisions, state-level tax and flavor legislation, and Big Tobacco capex as they develop. Subscribe to the briefing list to receive updates directly.
📚 Sources & Further Reading
Regulatory & FDA
- FDA Center for Tobacco Products — Authorization decisions & enforcement updates
- Continuum of Risk — FDA Authorizes Six on! PLUS Nicotine Pouch Products (December 2025)
- Vaping360 — FDA Authorizes First Nicotine Pouches Under Fast-Track Program
- CSP Daily News — 2026 Tobacco Regulations: What C-Stores Need to Know
Market Data & Industry Research
- Grand View Research — U.S. Nicotine Pouches Market Report ($4.09B / 29.6% CAGR)
- Global Market Insights — Nicotine Pouches Market Trends 2026-2035
- Transparency Market Research — Nicotine Pouches Analysis (PMI $600M Colorado)
- HDIN Research — U.S. & Europe Oral Nicotine Market Insights 2026 (Project Newark, Silicon Valley trend)
- Nicokick — 2024 Nicotine Pouch Report (brand share & flavor data)
Enforcement & Regulatory Actions
- CSP — FDA Actions & Tax Hikes Reshaped Back Bar in 2025
- Ecigator — “Seize and Destroy” Federal Authority Analysis
- VapeTM — FY2026 $200M Enforcement Allocation & State Directory Tracker
- Tobacco Insider — USA Illegal Vape Enforcement Tracker
- GAO Report (April 2026) — Vape Enforcement “Falling Short” Analysis (as reported by STAT News / HealthDay)
Health & Consumer Research
- American Cancer Society — What to Know About Nicotine Pouches and Cancer Risk
- Truth Initiative — Monitoring a Changing Tobacco Product Market (January 2026)
- BMC Oral Health — Systematic review of nicotine pouch oral health impact (2024)
Industry Channel / Distribution
- B&J Wholesale — Licensed U.S. B2B distributor (vape + pouch)
- B&J Wholesale — Nicotine Pouch Collection
- VapeOwls — U.S. adult-consumer retail platform
- VapeOwls — Consumer-facing nicotine pouches vs. vapes analysis
